Business Description
Cohance Lifesciences Ltd
ISIN : INE03QK01018
Total Employee Number:
2,295Compare
Compare
Traded in other countries / regions
543064.India IPO Date
2020-03-09Description
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.82 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.93 | |||||
Interest Coverage | 6.44 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 6.44 | |||||
Beneish M-Score | -1.02 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.2 | |||||
3-Year EBITDA Growth Rate | -22.7 | |||||
3-Year EPS without NRI Growth Rate | -30.6 | |||||
3-Year FCF Growth Rate | -16.8 | |||||
3-Year Book Growth Rate | 14.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37.79 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.35 | |||||
9-Day RSI | 42.26 | |||||
14-Day RSI | 44.75 | |||||
3-1 Month Momentum % | -5.75 | |||||
6-1 Month Momentum % | 19.51 | |||||
12-1 Month Momentum % | -54.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.83 | |||||
Quick Ratio | 1.96 | |||||
Cash Ratio | 0.51 | |||||
Days Inventory | 242.68 | |||||
Days Sales Outstanding | 83.41 | |||||
Days Payable | 124.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.5 | |||||
Shareholder Yield % | -1.87 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.79 | |||||
Operating Margin % | 10.56 | |||||
Net Margin % | 7.9 | |||||
EBITDA Margin % | 19.03 | |||||
FCF Margin % | 6.54 | |||||
OCF Margin % | 16.24 | |||||
ROE % | 5.72 | |||||
ROA % | 3.75 | |||||
ROIC % | 4.15 | |||||
3-Year ROIIC % | -5.75 | |||||
ROC (Joel Greenblatt) % | 9.37 | |||||
ROCE % | 5.78 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 92.71 | |||||
Forward PE Ratio | 43.48 | |||||
PE Ratio without NRI | 83.72 | |||||
Price-to-Owner-Earnings | 79.89 | |||||
PS Ratio | 7.34 | |||||
PB Ratio | 4.21 | |||||
Price-to-Tangible-Book | 6.44 | |||||
Price-to-Free-Cash-Flow | 111.24 | |||||
Price-to-Operating-Cash-Flow | 44.83 | |||||
EV-to-EBIT | 67.41 | |||||
EV-to-EBITDA | 38.15 | |||||
EV-to-Forward-EBITDA | 18.65 | |||||
EV-to-Revenue | 7.26 | |||||
EV-to-Forward-Revenue | 7.89 | |||||
EV-to-FCF | 108.95 | |||||
Price-to-GF-Value | 0.61 | |||||
Price-to-Projected-FCF | 2.57 | |||||
Price-to-Graham-Number | 4.86 | |||||
| Price-to-Net-Current-Asset-Value | 1701.6 | |||||
Earnings Yield (Greenblatt) % | 1.48 | |||||
FCF Yield % | 0.91 | |||||
Forward Rate of Return (Yacktman) % | -4.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cohance Lifesciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 22,685.5 | ||
| EPS (TTM) (₹) | 4.65 | ||
| Beta | 1.4045 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 78.57 | ||
| 14-Day RSI | 44.75 | ||
| 14-Day ATR (₹) | 15.314988 | ||
| 20-Day SMA (₹) | 437.0125 | ||
| 12-1 Month Momentum % | -54.37 | ||
| 52-Week Range (₹) | 267.85 - 1038 | ||
| Shares Outstanding (Mil) | 382.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cohance Lifesciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cohance Lifesciences Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 2:1 Stock Split | 2020-09-25 | 369.60 (+2.67%) |
Show
Entries
Cohance Lifesciences Ltd Frequently Asked Questions
What is Cohance Lifesciences Ltd(BOM:543064)'s stock price today?
The current price of BOM:543064 is ₹425.40. The 52 week high of BOM:543064 is ₹1038.00 and 52 week low is ₹267.85.
When is next earnings date of Cohance Lifesciences Ltd(BOM:543064)?
The next earnings date of Cohance Lifesciences Ltd(BOM:543064) is .
Does Cohance Lifesciences Ltd(BOM:543064) pay dividends? If so, how much?
Cohance Lifesciences Ltd(BOM:543064) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cohance Lifesciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers